Repligen Balance Sheet Health
Financial Health criteria checks 5/6
Repligen has a total shareholder equity of $2.1B and total debt of $537.9M, which brings its debt-to-equity ratio to 25.8%. Its total assets and total liabilities are $2.9B and $840.6M respectively. Repligen's EBIT is $60.1M making its interest coverage ratio -10. It has cash and short-term investments of $748.7M.
Key information
25.82%
Debt to equity ratio
US$537.93m
Debt
| Interest coverage ratio | -10x |
| Cash | US$748.75m |
| Equity | US$2.08b |
| Total liabilities | US$840.62m |
| Total assets | US$2.92b |
Recent financial health updates
Is Repligen (NASDAQ:RGEN) A Risky Investment?
Sep 01
Is Repligen (NASDAQ:RGEN) A Risky Investment?
Feb 12Recent updates
Repligen: Rare Growth In The Biopharma Supplies Industry
Nov 14Repligen's (NASDAQ:RGEN) Earnings May Just Be The Starting Point
Nov 12Repligen Corporation Just Beat EPS By 18%: Here's What Analysts Think Will Happen Next
Oct 31Why Investors Shouldn't Be Surprised By Repligen Corporation's (NASDAQ:RGEN) 28% Share Price Surge
Oct 04Is Repligen (NASDAQ:RGEN) A Risky Investment?
Sep 01Why Investors Shouldn't Be Surprised By Repligen Corporation's (NASDAQ:RGEN) P/S
Jul 29
Biomanufacturing Expansion Will Create New Global Opportunities
Strong demand in biomanufacturing and effective market expansion are driving sustained revenue growth and improved margins for Repligen.Repligen: Ongoing Bioprocessing Market Recovery
Mar 20Is Repligen (NASDAQ:RGEN) A Risky Investment?
Feb 12Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects
Nov 12Repligen: Strong Filtration Growth, Offset By Other Challenges
Jul 13Repligen Stock: Still Quite Overvalued
May 30Financial Position Analysis
Short Term Liabilities: RGEN's short term assets ($1.1B) exceed its short term liabilities ($131.1M).
Long Term Liabilities: RGEN's short term assets ($1.1B) exceed its long term liabilities ($709.5M).
Debt to Equity History and Analysis
Debt Level: RGEN has more cash than its total debt.
Reducing Debt: RGEN's debt to equity ratio has increased from 21.4% to 25.8% over the past 5 years.
Debt Coverage: RGEN's debt is well covered by operating cash flow (24.3%).
Interest Coverage: RGEN earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/20 05:20 |
| End of Day Share Price | 2025/11/20 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Repligen Corporation is covered by 31 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Luke Sergott | Barclays |
| Robert Wasserman | Benchmark Company |
| Hugo Solvet | BNP Paribas |